With its recently published study “Global Leukemia Therapeutics Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025”, Infoholic Research forecasts that the global leukemia therapeutics market will continue to grow, owing to increasing incidence of leukemia cases across the globe, rising elderly population, and advent of innovative therapies. A promising pipeline of the drug, increased approval of new drugs, and substantial opportunities in emerging economies are anticipated to support the market growth during the forecast period 2019–2025.

Request for sample report @ https://www.infoholicresearch.com/request-a-sample-report/?repid=14509

The global leukemia therapeutics market, by disease type, is segmented into chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), and acute myeloid leukemia (AML). Among these, the chronic myeloid leukemia segment accounted for the largest share and is expected to grow at a mid-single-digit CAGR by 2025. The increased prevalence rate of CML and the obtainability of huge number of treatment options make the segment the largest shareholder in the global leukemia therapeutics market. The market, in terms of molecule type analysis, is segmented into small molecules and biologics. The small molecules segment occupied a maximum share and biologics is expected to grow at a high CAGR during the forecast period 2019–2025.

In December 2019, Merck signed a definitive agreement to purchase cancer drug developer “ArQule” through an acquisition subsidiary, for $2.7 billion. If the deal is successful, Merck will get a promising early-stage compound that has the potential to challenge a blockbuster leukemia drug manufactured by the rival company “AbbVie”. ArQule’s leading investigational candidate ARQ 531 is a small molecule oral BTK inhibitor currently in Phase 2 dose-expansion study for the treatment of leukemia. Merck expects to finalize the transaction in the first quarter of 2020.

Access full report summary @ https://www.infoholicresearch.com/report/leukemia-therapeutics-market/

Many companies are gaining approvals for their drugs, which is aiding to have significant hold in the market. For instance, in December 2019, the FDA granted a supplemental approval to acalabrutinib (Calquence) developed by AstraZeneca to treat CLL or SLL.

The global leukemia therapeutics market is segmented in the regions of North America, Europe, Asia Pacific, and Rest of the World. North America held a significant market share in 2018 and is expected to grow at a mid-single-digit CAGR during the forecast period. The presence of established healthcare infrastructure, a high patient base for the disease, increasing awareness on personalized medicine, and the existence of reputed players in the region make North America a dominant shareholder in the global leukemia therapeutics market. Asia Pacific is likely to grow at the fastest rate during the forecast period due to the increasing occurrence of the disease, growing healthcare awareness, and rising disposable income.